Last Posted: Nov 08, 2018
- Pharmacogenetics to prevent heparin-induced thrombocytopenia: what do we know?
Karnes Jason H et al. Pharmacogenomics 2018 Nov
- Targeted resequencing of a locus for heparin-induced thrombocytopenia on chromosome 5 identified in a genome-wide association study.
Witten Anika, et al. Journal of molecular medicine (Berlin, Germany) 2018 6
- Influence of Human Leukocyte Antigen (HLA) Alleles and Killer Cell Immunoglobulin-Like Receptors (KIR) Types on Heparin-Induced Thrombocytopenia (HIT).
Karnes Jason H, et al. Pharmacotherapy 2017 7
- IVIg for Treatment of Severe Refractory Heparin-Induced Thrombocytopenia.
Padmanabhan Anand, et al. Chest 2017 4
- Polymorphism of the Fc? Receptor II as a Possible Predisposing Factor for Heparin-Induced Thrombocytopenia.
Slavik Ludek, et al. Clinical laboratory 2015 0 (8) 1027-32
- A genome-wide association study of heparin-induced thrombocytopenia using an electronic medical record.
Karnes Jason H, et al. Thrombosis and haemostasis 2015 4 (4) 772-81
- Polymorphisms of protein tyrosine phosphatase CD148 influence Fc?RIIA-dependent platelet activation and the risk of heparin-induced thrombocytopenia.
Rollin Jérôme, et al. Blood 2012 8 (6) 1309-16
- Heparin-induced thrombocytopenia: the role of platelets genetic polymorphisms.
Pamela S, et al. Platelets 2012 7
- Interleukin-10 promoter microsatellite polymorphisms influence the immune response to heparin and the risk of heparin-induced thrombocytopenia.
Pouplard Claire, et al. Thrombosis research 2012 4 (4) 465-9
- Heparin-induced thrombocytopenia
From NCATS Genetic and Rare Diseases Information Center
Rare Disease PHGKB is an online, continuously updated, searchable database of published scientific literature, CDC and NIH resources, and other information that address the public health impact and translation of genomic and other precision health discoveries into improved health outcomes related to rare diseases...more
Selected Rare Diseases
- Alpha-1 Antitrypsin Deficiency
- Amyotrophic Lateral Sclerosis
- Brugada Syndrome
- Cerebral Palsy
- Cystic Fibrosis
- Duchenne Muscular Dystrophy
- Erythema Multiforme
- Familial Mediterranean Fever
- Fragile X Syndrome
- Gaucher Disease
- Graves Disease
- Huntington Disease
- Myasthenia Gravis
- Retinitis Pigmentosa
- Severe Combined Immunodeficiency
Disclaimer: Articles listed in the Public Health Knowledge Base are selected by the CDC Office of Public Health Genomics to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.